Objective:To investigate the effects of nebulizedα-interferon on immune function in elderly patients with respiratory tract infection.Methods:A total of 120 elderly patients with respiratory tract infection admitted ...Objective:To investigate the effects of nebulizedα-interferon on immune function in elderly patients with respiratory tract infection.Methods:A total of 120 elderly patients with respiratory tract infection admitted to our hospital from June 2023 to June 2024 were selected and randomly divided into an observation group(n=60)and a control group(n=60)using the envelope method.The control group received conventional treatment,while the observation group received additional nebulizedα-interferon therapy based on conventional treatment.After the same treatment period,changes in immune function indicators(immunoglobulins IgG,IgA,IgM)were compared between the two groups.Patients were also followed up for 3 months to observe the frequency of respiratory tract infection recurrences.Results:After treatment,IgA and IgM levels decreased significantly,while IgG levels increased significantly in both groups.The improvement in each indicator was more pronounced in the observation group than in the control group(P<0.05).By the end of the follow-up period,all 120 patients had successfully completed the follow-up,and no patients were lost to follow-up.The frequency of respiratory tract infection recurrences was lower in the observation group than in the control group(P<0.05).Conclusion:Nebulizedα-interferon can improve immune function and reduce the frequency of recurrences in elderly patients with respiratory tract infection.展开更多
Objective:To analyze the factors affecting the efficacy ofα-interferon in the treatment of chronic hepatitis B(CHB).Methods:A total of 100 patients with CHB treated in our hospital from June 2018 to June 2019 were se...Objective:To analyze the factors affecting the efficacy ofα-interferon in the treatment of chronic hepatitis B(CHB).Methods:A total of 100 patients with CHB treated in our hospital from June 2018 to June 2019 were selected.All patients were treated withα-interferon to evaluate the efficacy,and the factors affecting the effect ofα-interferon on CHB were analyzed.Results:After treatment,54 patients fully responded and 46 patients did not;the levels of white blood cells,HBV DNA,and HBsAg in the complete response group were lower than those in the incompletely response group,and the differences were statistically significant(P<0.05);Multivariate logistic regression analysis found that serum HBV DNA and HBsAg were independent factors affecting the efficacy ofα-interferon in the treatment of CHB(OR>1,P<0.05).Conclusion:Serum HBV DNA and HBsAg are risk factors that affect the efficacy ofα-interferon in the treatment of CHB.Monitoring the changes of serum HBV DNA and HBsAg levels has important clinical significance for predicting the efficacy.展开更多
Objective: To study the effect of α-interferon + gemcitabine combined with infusion chemotherapy on the proliferation and infiltrative growth of advanced bladder cancer. Methods: Patients with advanced bladder cancer...Objective: To study the effect of α-interferon + gemcitabine combined with infusion chemotherapy on the proliferation and infiltrative growth of advanced bladder cancer. Methods: Patients with advanced bladder cancer who accepted bladder infusion chemotherapy in Wuhan Red Cross Hospital between March 2015 and August 2016 were selected and randomly divided into the IFN-α+GEM group and the GEM group who acceptedα-interferon + gemcitabine combined with infusion chemotherapy and single gemcitabine infusion chemotherapy respectively. The contents of bladder cancer markers, cancer cell apoptosis molecules and angiogenesis molecules in urine were detected before treatment and 3 months after treatment. Results: 3 months after treatment, NMP-22, BLCA-4, Apo-A1, HA, CYFRA21-1, ANG, NAC-1, VEGF and bFGF levels in urine of both groups of patients were significantly lower than those before treatment while PTEN, TRAIL, Bim, HSG and p16 levels were significantly higher than those before treatment, and NMP-22, BLCA-4, Apo-A1, HA, CYFRA21-1, ANG, NAC-1, VEGF and bFGF levels in urine of IFN-α+GEM group were significantly lower than those of GEM group while PTEN, TRAIL, Bim, HSG and p16 levels were significantly higher than those of GEM group. Conclusion: α-interferon + gemcitabine combined with infusion chemotherapy can be more effective than single gemcitabine infusion chemotherapy in killing cancer cells and inhibiting the proliferation and infiltrative growth of the cancer cells.展开更多
目的基于网状Meta分析系统评价重组干扰素α-2b治疗小儿疱疹性咽峡炎的疗效及安全性。方法计算机检索中国生物医学文献(CBM)、中国知网、万方、维普、读秀、Ovid、Cochrane Library、Embase、PubMed、Web of Science等数据库,纳入重组...目的基于网状Meta分析系统评价重组干扰素α-2b治疗小儿疱疹性咽峡炎的疗效及安全性。方法计算机检索中国生物医学文献(CBM)、中国知网、万方、维普、读秀、Ovid、Cochrane Library、Embase、PubMed、Web of Science等数据库,纳入重组干扰素α-2b治疗疱疹性咽峡炎患儿(年龄≤7岁)的随机对照试验,检索时限为建库至2024年2月27日。2名独立的研究者遵循纳入与排除标准,采用改良后的Jadad量表和Cochrane偏倚风险评估工具,对文献进行筛选、资料提取和质量评价。提取临床总有效率、退热时间、疱疹消失时间、恢复进食时间、住院时间及不良反应发生率等结局指标,通过Stata16.0软件对筛选出的文献进行Meta网状分析。结果最终纳入24篇文献,共计3078例疱疹性咽峡炎患儿,对照组干预措施包括利巴韦林、常规治疗、喜炎平、开喉剑及热毒宁等。网状Meta分析结果显示,与对照组不同干预措施相比,试验组采用重组干扰素α-2b可提高临床总有效率,缩短退热时间、疱疹消失时间、恢复进食时间、住院时间(P均<0.05),且不会增加不良反应发生率。结论对比其他治疗方案,使用重组干扰素α-2b治疗小儿疱疹性咽峡炎疗效显著,安全性较高。展开更多
目的探究EB病毒(EBV)感染对系统性红斑狼疮(SLE)患者免疫应答的影响。方法收集2022年5月至2024年4月收治的SLE患者103例(SLE组)、类风湿关节炎(RA)患者50例(RA组);另收集2023年5月至2024年4月体检的健康人群120例作为对照组。采用直接...目的探究EB病毒(EBV)感染对系统性红斑狼疮(SLE)患者免疫应答的影响。方法收集2022年5月至2024年4月收治的SLE患者103例(SLE组)、类风湿关节炎(RA)患者50例(RA组);另收集2023年5月至2024年4月体检的健康人群120例作为对照组。采用直接化学发光磁微粒间接免疫技术检测3组抗EBV CA IgG抗体、抗EBV CA IgA抗体、抗EBV CA IgM抗体、抗EBV EA IgM抗体、抗EBV NA IgG抗体和抗EBV NA IgA抗体水平,比较各组阳性率。根据抗EBV抗体结果将SLE组分为重新激活感染组和既往感染组,检测非特异性和特异性免疫应答指标。采用流式分选技术分离两组患者外周血T淋巴细胞,进行转录组测序。结果抗EBV CA IgA抗体在SLE组中的阳性率[22.33%(23/103)]高于RA组[6.00%(3/50)]和对照组[5.00%(6/120)],差异有统计学意义(P<0.05)。SLE患者抗EBV EA IgM抗体与α-干扰素呈正相关(r=0.1984,P<0.05);抗EBV CA IgM抗体与白细胞介素-2(IL-2)、IL-5、IL-1β呈正相关(r=0.1980、0.2553、0.1797,P<0.05);抗EBV CA IgG抗体与IL-5(r=0.2769,P<0.05)、IL-2(r=0.1820,P<0.05)、IL-8(r=0.1920,P<0.05)、γ-干扰素(r=0.1807,P<0.05)呈正相关。抗EBV NA IgG抗体与IL-4(r=0.2015,P<0.05)、IL-8(r=0.2395,P<0.05)、IL-17(r=0.1795,P<0.05)呈正相关,与IL-5(r=-0.2212,P<0.05)呈负相关。SLE患者抗EBV NA IgG抗体与IgG呈正相关(r=0.2731,P<0.05),抗EBV CA IgM抗体与IgM呈正相关(r=0.2614,P<0.05),抗EBV EA IgM抗体与白细胞计数(r=-0.2742,P<0.05)、中性粒细胞计数(r=-0.2249,P<0.05)、淋巴细胞计数(r=-0.2723,P<0.05)、单核细胞计数(r=-0.2275,P<0.05)呈负相关,抗EBV NA IgA抗体与IgA呈正相关(r=0.3231,P<0.05)。抗EBV CA IgA抗体阳性SLE组与抗EBV CA IgA抗体阴性SLE组、RA组、对照组相比非特异性免疫应答指标IgA升高,C3、C4降低(P<0.05);抗EBV CA IgA抗体阳性SLE组与RA组、对照组比较,特异性免疫应答指标CD16^(+)56^(+)、CD19、CD4/CD8比值降低(P<0.05)。外周血T淋巴细胞转录组测序分析结果显示,与既往感染组比较,重新激活感染组IL-2、IL-5、IL-8及γ-干扰素显著上调(P<0.05)。两组差异基因富集分析结果显示,差异基因相关信号通路主要为“炎症反应激活”“炎性小体形成”“炎性因子释放”等炎症信号通路。结论SLE患者EBV感染活跃性更高。EBV感染可能通过激活Th1/Th2免疫应答,加剧SLE的炎症微环境。EBV感染促进SLE患者体液免疫激活。展开更多
Objective To study the effect of γ-interferon （IFNγ）, tumor necrosis factor related apoptosis inducing ligand （TRAIL）, and cisplatin or etoposide induced apoptosis in human neuroblastoma cell line SH-SY5Y and it...Objective To study the effect of γ-interferon （IFNγ）, tumor necrosis factor related apoptosis inducing ligand （TRAIL）, and cisplatin or etoposide induced apoptosis in human neuroblastoma cell line SH-SY5Y and its possible molecular mechanisms. Methods The expressions of Caspase 8 mRNA and protein were detected with RT-PCR and Western blot analysis. The effects of IFNγ, TRAIL, IFNγ ＋ TRAIL, IFNγ ＋ Caspase 8 inhibitor ＋ TRAIL, IFNγ ＋ cisplatin ＋ TRAIL, and IFNγ ＋ etoposide ＋ TRAIL on the growth and apoptosis of SH-SY5Y cells were detected with the methods of MTT and flow cytometry. The relative Caspase 8 activity was measured with colorimetric assay. Results Caspase 8 was undetectable in SH-SY5Y cells but an increased expression of Caspase 8 mRNA and protein was found after treatment with IFNγ. SH-SY5Y ceils themselves were not sensitive to TRAIL, but those expressing Caspase 8 after treatment with IFNγ were. The killing effect of TRAIL on SH-SY5Y cells expressing Caspase 8 was depressed by Caspase 8 inhibitor. Cisplatin and etoposide could enhance the sensitivity of TRAIL on SH-SY5Y cells. The relative Caspase 8 activity of SH-SY5Y cells in IFNγ ＋ TRAIL group was significantly higher than those of control group, IFNγ group, TRAIL group, and inhibitor group （ P 〈 0. 01 ）. There was no significant difference among IFNγ ＋ TRAIL group, IFNγ ＋ cisplatin ＋ TRAIL group, and IFNγ ＋ etoposide ＋ TRAIL group. Conclusions IFNγ could sensitize SH-SY5Y cells to TRAIL-induced apoptosis and this may be realized by the up-regulation of Caspase 8. Cisplatin and etoposide could enhance the killing effect of TRAIL on SH-SY5Y cells.展开更多
文摘Objective:To investigate the effects of nebulizedα-interferon on immune function in elderly patients with respiratory tract infection.Methods:A total of 120 elderly patients with respiratory tract infection admitted to our hospital from June 2023 to June 2024 were selected and randomly divided into an observation group(n=60)and a control group(n=60)using the envelope method.The control group received conventional treatment,while the observation group received additional nebulizedα-interferon therapy based on conventional treatment.After the same treatment period,changes in immune function indicators(immunoglobulins IgG,IgA,IgM)were compared between the two groups.Patients were also followed up for 3 months to observe the frequency of respiratory tract infection recurrences.Results:After treatment,IgA and IgM levels decreased significantly,while IgG levels increased significantly in both groups.The improvement in each indicator was more pronounced in the observation group than in the control group(P<0.05).By the end of the follow-up period,all 120 patients had successfully completed the follow-up,and no patients were lost to follow-up.The frequency of respiratory tract infection recurrences was lower in the observation group than in the control group(P<0.05).Conclusion:Nebulizedα-interferon can improve immune function and reduce the frequency of recurrences in elderly patients with respiratory tract infection.
文摘Objective:To analyze the factors affecting the efficacy ofα-interferon in the treatment of chronic hepatitis B(CHB).Methods:A total of 100 patients with CHB treated in our hospital from June 2018 to June 2019 were selected.All patients were treated withα-interferon to evaluate the efficacy,and the factors affecting the effect ofα-interferon on CHB were analyzed.Results:After treatment,54 patients fully responded and 46 patients did not;the levels of white blood cells,HBV DNA,and HBsAg in the complete response group were lower than those in the incompletely response group,and the differences were statistically significant(P<0.05);Multivariate logistic regression analysis found that serum HBV DNA and HBsAg were independent factors affecting the efficacy ofα-interferon in the treatment of CHB(OR>1,P<0.05).Conclusion:Serum HBV DNA and HBsAg are risk factors that affect the efficacy ofα-interferon in the treatment of CHB.Monitoring the changes of serum HBV DNA and HBsAg levels has important clinical significance for predicting the efficacy.
文摘Objective: To study the effect of α-interferon + gemcitabine combined with infusion chemotherapy on the proliferation and infiltrative growth of advanced bladder cancer. Methods: Patients with advanced bladder cancer who accepted bladder infusion chemotherapy in Wuhan Red Cross Hospital between March 2015 and August 2016 were selected and randomly divided into the IFN-α+GEM group and the GEM group who acceptedα-interferon + gemcitabine combined with infusion chemotherapy and single gemcitabine infusion chemotherapy respectively. The contents of bladder cancer markers, cancer cell apoptosis molecules and angiogenesis molecules in urine were detected before treatment and 3 months after treatment. Results: 3 months after treatment, NMP-22, BLCA-4, Apo-A1, HA, CYFRA21-1, ANG, NAC-1, VEGF and bFGF levels in urine of both groups of patients were significantly lower than those before treatment while PTEN, TRAIL, Bim, HSG and p16 levels were significantly higher than those before treatment, and NMP-22, BLCA-4, Apo-A1, HA, CYFRA21-1, ANG, NAC-1, VEGF and bFGF levels in urine of IFN-α+GEM group were significantly lower than those of GEM group while PTEN, TRAIL, Bim, HSG and p16 levels were significantly higher than those of GEM group. Conclusion: α-interferon + gemcitabine combined with infusion chemotherapy can be more effective than single gemcitabine infusion chemotherapy in killing cancer cells and inhibiting the proliferation and infiltrative growth of the cancer cells.
文摘目的基于网状Meta分析系统评价重组干扰素α-2b治疗小儿疱疹性咽峡炎的疗效及安全性。方法计算机检索中国生物医学文献(CBM)、中国知网、万方、维普、读秀、Ovid、Cochrane Library、Embase、PubMed、Web of Science等数据库,纳入重组干扰素α-2b治疗疱疹性咽峡炎患儿(年龄≤7岁)的随机对照试验,检索时限为建库至2024年2月27日。2名独立的研究者遵循纳入与排除标准,采用改良后的Jadad量表和Cochrane偏倚风险评估工具,对文献进行筛选、资料提取和质量评价。提取临床总有效率、退热时间、疱疹消失时间、恢复进食时间、住院时间及不良反应发生率等结局指标,通过Stata16.0软件对筛选出的文献进行Meta网状分析。结果最终纳入24篇文献,共计3078例疱疹性咽峡炎患儿,对照组干预措施包括利巴韦林、常规治疗、喜炎平、开喉剑及热毒宁等。网状Meta分析结果显示,与对照组不同干预措施相比,试验组采用重组干扰素α-2b可提高临床总有效率,缩短退热时间、疱疹消失时间、恢复进食时间、住院时间(P均<0.05),且不会增加不良反应发生率。结论对比其他治疗方案,使用重组干扰素α-2b治疗小儿疱疹性咽峡炎疗效显著,安全性较高。
文摘目的探究EB病毒(EBV)感染对系统性红斑狼疮(SLE)患者免疫应答的影响。方法收集2022年5月至2024年4月收治的SLE患者103例(SLE组)、类风湿关节炎(RA)患者50例(RA组);另收集2023年5月至2024年4月体检的健康人群120例作为对照组。采用直接化学发光磁微粒间接免疫技术检测3组抗EBV CA IgG抗体、抗EBV CA IgA抗体、抗EBV CA IgM抗体、抗EBV EA IgM抗体、抗EBV NA IgG抗体和抗EBV NA IgA抗体水平,比较各组阳性率。根据抗EBV抗体结果将SLE组分为重新激活感染组和既往感染组,检测非特异性和特异性免疫应答指标。采用流式分选技术分离两组患者外周血T淋巴细胞,进行转录组测序。结果抗EBV CA IgA抗体在SLE组中的阳性率[22.33%(23/103)]高于RA组[6.00%(3/50)]和对照组[5.00%(6/120)],差异有统计学意义(P<0.05)。SLE患者抗EBV EA IgM抗体与α-干扰素呈正相关(r=0.1984,P<0.05);抗EBV CA IgM抗体与白细胞介素-2(IL-2)、IL-5、IL-1β呈正相关(r=0.1980、0.2553、0.1797,P<0.05);抗EBV CA IgG抗体与IL-5(r=0.2769,P<0.05)、IL-2(r=0.1820,P<0.05)、IL-8(r=0.1920,P<0.05)、γ-干扰素(r=0.1807,P<0.05)呈正相关。抗EBV NA IgG抗体与IL-4(r=0.2015,P<0.05)、IL-8(r=0.2395,P<0.05)、IL-17(r=0.1795,P<0.05)呈正相关,与IL-5(r=-0.2212,P<0.05)呈负相关。SLE患者抗EBV NA IgG抗体与IgG呈正相关(r=0.2731,P<0.05),抗EBV CA IgM抗体与IgM呈正相关(r=0.2614,P<0.05),抗EBV EA IgM抗体与白细胞计数(r=-0.2742,P<0.05)、中性粒细胞计数(r=-0.2249,P<0.05)、淋巴细胞计数(r=-0.2723,P<0.05)、单核细胞计数(r=-0.2275,P<0.05)呈负相关,抗EBV NA IgA抗体与IgA呈正相关(r=0.3231,P<0.05)。抗EBV CA IgA抗体阳性SLE组与抗EBV CA IgA抗体阴性SLE组、RA组、对照组相比非特异性免疫应答指标IgA升高,C3、C4降低(P<0.05);抗EBV CA IgA抗体阳性SLE组与RA组、对照组比较,特异性免疫应答指标CD16^(+)56^(+)、CD19、CD4/CD8比值降低(P<0.05)。外周血T淋巴细胞转录组测序分析结果显示,与既往感染组比较,重新激活感染组IL-2、IL-5、IL-8及γ-干扰素显著上调(P<0.05)。两组差异基因富集分析结果显示,差异基因相关信号通路主要为“炎症反应激活”“炎性小体形成”“炎性因子释放”等炎症信号通路。结论SLE患者EBV感染活跃性更高。EBV感染可能通过激活Th1/Th2免疫应答,加剧SLE的炎症微环境。EBV感染促进SLE患者体液免疫激活。
基金the National Natural Sciences Foundation of China(39470739)the Ministry of Public Health Research Foundation(20122167)the Doctor Startup-Natural Science Foundation of Li-aoning Province (20041047)
文摘Objective To study the effect of γ-interferon （IFNγ）, tumor necrosis factor related apoptosis inducing ligand （TRAIL）, and cisplatin or etoposide induced apoptosis in human neuroblastoma cell line SH-SY5Y and its possible molecular mechanisms. Methods The expressions of Caspase 8 mRNA and protein were detected with RT-PCR and Western blot analysis. The effects of IFNγ, TRAIL, IFNγ ＋ TRAIL, IFNγ ＋ Caspase 8 inhibitor ＋ TRAIL, IFNγ ＋ cisplatin ＋ TRAIL, and IFNγ ＋ etoposide ＋ TRAIL on the growth and apoptosis of SH-SY5Y cells were detected with the methods of MTT and flow cytometry. The relative Caspase 8 activity was measured with colorimetric assay. Results Caspase 8 was undetectable in SH-SY5Y cells but an increased expression of Caspase 8 mRNA and protein was found after treatment with IFNγ. SH-SY5Y ceils themselves were not sensitive to TRAIL, but those expressing Caspase 8 after treatment with IFNγ were. The killing effect of TRAIL on SH-SY5Y cells expressing Caspase 8 was depressed by Caspase 8 inhibitor. Cisplatin and etoposide could enhance the sensitivity of TRAIL on SH-SY5Y cells. The relative Caspase 8 activity of SH-SY5Y cells in IFNγ ＋ TRAIL group was significantly higher than those of control group, IFNγ group, TRAIL group, and inhibitor group （ P 〈 0. 01 ）. There was no significant difference among IFNγ ＋ TRAIL group, IFNγ ＋ cisplatin ＋ TRAIL group, and IFNγ ＋ etoposide ＋ TRAIL group. Conclusions IFNγ could sensitize SH-SY5Y cells to TRAIL-induced apoptosis and this may be realized by the up-regulation of Caspase 8. Cisplatin and etoposide could enhance the killing effect of TRAIL on SH-SY5Y cells.
